Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis

We report our experience with the combination of anti‐thymocyte globulin (ATGAM) and tacrolimus in the treatment of 20 patients with steroid refractory and dependent acute graft‐versus‐host disease (GVHD) transplanted between August 1996 and February 2000. All patients received cyclosporine‐based GV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2001-04, Vol.113 (1), p.217-223
Hauptverfasser: Durrant, S., Mollee, P., Morton, A. J., Irving, I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We report our experience with the combination of anti‐thymocyte globulin (ATGAM) and tacrolimus in the treatment of 20 patients with steroid refractory and dependent acute graft‐versus‐host disease (GVHD) transplanted between August 1996 and February 2000. All patients received cyclosporine‐based GVHD prophylaxis. Thirteen patients developed a maximum of grade IV, five grade III and two grade II acute GVHD, with 15 patients being refractory to steroids and five dependent on steroids. Patients were treated with ATGAM (15 mg/kg for 5 d) and tacrolimus (0·025–0·1 mg/kg/d) in addition to continuation of their high‐dose steroids and cessation of their cyclosporine. Within 28 d of treatment, we observed eight complete responses (CR), six partial responses (PR) and six with no response. Overall response (CR + PR) was predicted by GVHD severity. Infectious complications occurred in 80% of patients. The median survival was 86·5 d (range, 21–1081 d) with 35% of patients remaining alive. Survival following combination therapy was significantly more likely in men (P 
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2001.02741.x